Iovance Biotherapeutics
IOVA
$8.29
-7.79%
Iovance Biotherapeutics is a clinical-stage biopharmaceutical company pioneering tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors, with its lead product Amtagvi (lifileucel) approved by the FDA for advanced melanoma. The company is a first-mover in autologous TIL therapy, positioning itself as a leader in personalized cell therapy for solid tumors, a challenging area where others have struggled. The current investor narrative centers on the commercial ramp of Amtagvi following strong Q2 2026 earnings, which drove a significant stock surge, while debates persist about the pace of adoption, manufacturing scalability, and the path to profitability as the company expands its pipeline into other indications.…
IOVA
Iovance Biotherapeutics
$8.29
Related headlines
Investment Opinion: Should I buy IOVA Today?
Iovance is rated a Buy based on strong revenue growth, improving margins, and a first-mover advantage in TIL therapy, with analyst consensus at 'buy' and an average target price of $9.33, implying 12.5% upside. The thesis is supported by 44.8% YoY revenue growth, a 98.6% gross margin, narrowing net losses, and a PEG ratio of 0.17, suggesting the stock is undervalued relative to its growth potential. However, the negative operating margin and cash burn are significant risks that could invalidate the thesis if not addressed.
Sign up to view all
IOVA 12-Month Price Forecast
The AI model assesses Iovance as a bullish opportunity given its strong revenue acceleration, exceptional gross margins, and narrowing losses. The stock's valuation, with a PS ratio of 3.70x below the industry average, suggests it is not overvalued relative to growth. However, the high cash burn and execution risks temper confidence to medium. The stance would be upgraded to high confidence if the company achieves profitability or secures additional approvals, while a downgrade would occur if revenue growth decelerates below 20% or if clinical setbacks emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Iovance Biotherapeutics's 12-month outlook, with a consensus price target around $9.67 and implied upside of +16.6% versus the current price.
Average Target
$9.67
0 analysts
Implied Upside
+16.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$6 - $14
Analyst target range
Iovance is covered by 9 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.67 (where 1 is strong buy and 5 is sell). The average target price is $9.33, implying a 12.5% upside from the current price of $8.29. The distribution includes 7 buys, 1 hold, and 1 sell, indicating a generally bullish sentiment but with some caution. The target price range spans from $4.00 low to $14.00 high, reflecting significant uncertainty about the company's commercial execution and pipeline potential. The high target of $14.00 assumes successful expansion of Amtagvi into earlier lines of therapy and additional indications, while the low target of $4.00 prices in potential commercial disappointments or competitive pressures. Recent ratings actions have been positive, with Chardan Capital reiterating Buy and Citizens upgrading to Market Outperform in early 2026, while UBS maintains a Neutral stance, suggesting a mixed but improving outlook.
Bulls vs Bears: IOVA Investment Factors
Iovance presents a compelling growth story with accelerating revenue, exceptional gross margins, and a first-mover advantage in TIL therapy, but it remains deeply unprofitable with significant cash burn and execution risks. The bull case is supported by strong Q2 2026 earnings and analyst optimism, while the bear case hinges on the sustainability of commercial ramp and the path to profitability. Currently, the bull side has stronger evidence given the revenue trajectory and narrowing losses, but the key tension is whether Amtagvi's adoption can scale fast enough to justify the premium valuation and eventually reach profitability. The stock's 226% 1-year gain reflects high expectations, making it vulnerable to any misstep in execution.
Bullish
- Revenue growth accelerating: Q1 2026 revenue of $71.4M grew 44.8% YoY from $49.3M, with sequential growth from Q2 2025's $59.95M to Q4 2025's $86.77M. The commercial ramp of Amtagvi is driving strong top-line momentum, indicating successful market adoption.
- High gross margin of 98.6%: Gross margin in Q1 2026 was 98.6%, reflecting the high-value nature of the personalized cell therapy. This exceptional margin provides a strong foundation for future profitability as operating expenses scale.
- Narrowing losses and improving leverage: Net loss improved from -$116.2M in Q1 2025 to -$79.0M in Q1 2026, a 32% reduction. Operating margin improved from -245.8% to -153.1% YoY, showing the company is gaining operational efficiency as revenue grows.
- Strong analyst consensus and upside: With 9 analysts, consensus is 'buy' (mean score 1.67) and average target price is $9.33, implying 12.5% upside from $8.29. The high target of $14.00 suggests potential for 68.9% upside if pipeline and commercial execution exceed expectations.
Bearish
- Deeply negative operating margins: Operating margin was -153.1% in Q1 2026, with operating expenses of $151.5M versus revenue of $71.4M. Heavy R&D and commercialization spending will continue to pressure profitability for the foreseeable future.
- Negative free cash flow and cash burn: TTM free cash flow is -$305.0M, indicating significant cash burn. While the company has a current ratio of 3.2, sustained losses may require additional capital raises, potentially diluting shareholders.
- Valuation premium on EV/Sales: EV/Sales is 11.76x, significantly higher than the PS ratio of 3.70x, reflecting a large premium for future growth. This leaves little room for error; any commercial disappointment could trigger multiple compression.
- Execution and manufacturing risks: Autologous TIL therapy is complex and personalized, with manufacturing scalability a key challenge. Delays or quality issues in production could hamper revenue growth and erode investor confidence.
IOVA Technical Analysis
Iovance's stock has been in a powerful uptrend over the past year, with a 1-year price change of +226.4%, dramatically outperforming the S&P 500's +20.5% gain. The current price of $8.29 sits at 88.6% of its 52-week range (between $1.76 low and $9.36 high), indicating strong momentum and investor optimism, though it is slightly off the recent high of $9.36. This positioning near the upper end of the range suggests the market is rewarding the company's commercial progress, but also leaves the stock vulnerable to profit-taking if near-term expectations are not met.
Beta
0.70
0.70x market volatility
Max Drawdown
-54.4%
Largest decline past year
52-Week Range
$2-$9
Price range past year
Annual Return
+226.4%
Cumulative gain past year
| Period | IOVA Return | S&P 500 |
|---|---|---|
| 1m | +60.3% | +3.6% |
| 3m | +101.7% | +2.7% |
| 6m | +188.9% | +11.4% |
| 1y | +226.4% | +18.7% |
| ytd | +229.0% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IOVA Fundamental Analysis
Iovance's revenue trajectory is accelerating, with Q1 2026 revenue of $71.4 million, up 44.8% year-over-year from $49.3 million in Q1 2025. Sequential growth is also robust, with revenue increasing from $59.95 million in Q2 2025 to $86.77 million in Q4 2025, though Q1 2026 saw a slight dip from Q4. The company's gross margin is exceptionally high at 98.6% in Q1 2026, reflecting the high-value nature of its cell therapy, but operating margins are deeply negative at -153.1% due to heavy R&D and commercialization expenses. Net income remains negative, with a net loss of $79.0 million in Q1 2026, though losses are narrowing from -$116.2 million in Q1 2025, indicating improving operational leverage.
Quarterly Revenue
$71430000.0B
2026-03
Revenue YoY Growth
+44.8%
YoY Comparison
Gross Margin
98.6%
Latest Quarter
Free Cash Flow
$-305021000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IOVA Overvalued?
Given Iovance's negative net income and EBITDA, the most appropriate valuation metric is the price-to-sales (PS) ratio, which stands at 3.70x trailing, while the forward PS is not provided. The EV-to-sales ratio is 11.76x, reflecting a significant premium to the company's current revenue base. The trailing PS of 3.70x is below the historical average of around 20x seen in 2024-2025, suggesting the market is pricing in substantial future revenue growth, but the forward PE of -31.18x indicates continued losses are expected. Compared to the biotechnology industry average PS ratio of approximately 5.0x, Iovance trades at a 26% discount, which may be justified by its early-stage commercial ramp and high risk profile. Historically, Iovance's PS ratio has ranged from 0x (pre-revenue) to over 5000x in 2023, and the current 3.70x is near the lower end of its historical band, suggesting the stock is not overvalued relative to its own past, but this reflects the market's adjustment to a more mature revenue base.
PE
-2.5x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-2.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial: Iovance has negative operating margins of -153.1% and a net loss of $79.0M in Q1 2026, with TTM free cash flow of -$305.0M. The company's debt-to-equity is low at 0.07, but its cash burn rate implies a need for future capital raises, which could dilute existing shareholders. Revenue concentration is high, with Amtagvi being the sole approved product, and any disruption in manufacturing or supply chain could severely impact financials. The current ratio of 3.2 provides some liquidity buffer, but sustained losses could erode this over time.